Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.10
Bid: 3.00
Ask: 3.20
Change: -0.20 (-6.06%)
Spread: 0.20 (6.667%)
Open: 3.30
High: 3.30
Low: 3.05
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Morrisons Sales Decline Sinks Shares

Thu, 07th May 2015 10:26

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 WINNERS
-------
RSA Insurance Group, up 1.2%. The insurer cautioned that lower interest rates and currency moves in its vital areas of business are having an unwelcome effect on business, but said its net profit in the first quarter of 2015 was "a little ahead" of plans and included gains it is expecting to make on asset sales.

EasyJet, up 0.3%. The airline said it flew 6.0 million passengers in April, up from 5.8 million a year earlier, while its load factor, a measure of how many paid seats are filled on its planes, rose to 90.8% from 89.8%. For the 12 months to the end of April, it flew 66.2 million passengers, up from 62.4 million in the previous 12 months, while its load factor improved to 91.0% from 89.7%. The increase came despite easyJet cancelling 602 flights in April compared with 48 a year earlier, mainly due to air traffic control strikes in France.
-------
FTSE 100 LOSERS
-------
WM Morrison Supermarkets, down 6.8%. The supermarket chain reported a drop in sales in its first quarter but said the company's financial position remains "strong" as it predicted higher profit in the second half of its financial year than in the first. The grocer said total sales in the 13 weeks to May 3 were down 5.1% on the same period a year earlier, while like-for-like sales were down 6.6%.

Admiral Group, down 4.5%, G4S, down 3.6%, and BP, down 2.7%. The stocks are down after going ex-dividend, meaning new buyers no longer qualify for the latest dividend payouts.

Barclays, down 2.4%. Four big banks are expected to plead guilty to rigging foreign-currency exchange rates and pay billions in combined penalties as part of settlement agreements expected to be announced as early as next week, the Wall Street Journal reported citing people familiar with the matter. The report indicated that US prosecutors are preparing to announce separate settlements simultaneously with Citigroup Inc, Barclays, JPMorgan Chase & Co and The Royal Bank of Scotland Group.
-------
FTSE 250 WINNERS
-------
Telecity Group, up 19%. The company said it has received a takeover approach from American data-centre provider Equinix Inc, a few months after agreeing an all-share deal to acquire data-centre services provider Interxion Holding NV. Telecity also reiterated its guidance for 2015. Equinix has approached with a potential offer of 1,145 pence per share, payable in a mixture of cash and stock in Equinix. Around 54% of the consideration would be payable in cash, and 46% in Equinix stock. Telecity currently trades at 1,066.50p.

Esure Group, up 1.2%. The insurer said it increased motor gross written premiums in the first quarter of 2015 and made some progress on its pricing. It said total gross written premiums increased to GBP130.7 million in the three months ended March 31, compared with GBP123.5 million in the corresponding quarter of the prior year. In-force policies increased to 1.971 million from 1.962 million at the same stage of the prior year. Additional services revenue was down 1.2% to GBP23.4 million.
-------
FTSE 250 LOSERS
-------
Henderson Group, down 4.4%, Morgan Advanced Materials, down 3.9%, Acacia Mining, down 3.6%, and Rightmove, down 3.2%. The stocks have gone ex-dividend.

Millennium & Copthorne, down 4.2%. The hotels operator reported lower profit in its first quarter, despite a rise in revenue and in revenue per available room, as profit was hit by labour cost pressures and a tough comparative in 2014. It said pretax profit in the three months to March 31 declined to GBP19 million from GBP20 million the year before. This was despite an increase in revenue to GBP189 million from GBP175 million and a rise in revenue per available room to GBP61.60 from GBP58.23.

IMI, down 4.1%. The engineering company said its market conditions remained challenging in the first quarter of 2015 and said its revenue dropped on the back of foreign exchange movements and contract delays. IMI said its revenue in the first quarter to the end of March was down 4% year-on-year, reflecting the ongoing damage to its results from the strength of sterling, though this was partially offset by an initial contribution from German power valve company Bopp & Reuther, which it acquired in 2014.
-------
AIM ALL-SHARE WINNERS
-------
Sareum Holdings, up 20%. The cancer drug discovery and development company said its equity swap deal with YA Global Master SPV Ltd has concluded ahead of schedule. Sareum said YA Global Master will remain an ordinary shareholder in the company, with a 1.15% stake, but said there are no further obligations under the equity swap agreement.

Stellar Diamonds, up 16%. The company said it will hold its next diamond sale of up to 4,439 carats from trial mining at the Baoulé kimberlite project in Guinea in Dubai and Antwerp via the eDiamond auction platform this month. Stellar said the sale will include gem quality stones of up to 12.6 carats in size and is part of its anticipated regular sales process from Baoulé, where it is targeting a total of 15,000 carats in order to establish the diamond grade at the project.

Tiziana Life Sciences, up 14%. The company said it has licensed from Cardiff University scientists a new anti-cancer stem cell agent capable of targeting aggressive tumours forming from cells originating in the breast, pancreas, colon and prostate.

ValiRx, up 7.4%. The life sciences company said it has signed a contract with bioanalytical chemistry and research company Admescope Ltd for access to the TRAC Finnish gene expression and biomarker technology. ValiRx acquired the assets and intellectual property rights of TRAC at the start of 2015. Under the agreement, on which no financial details were disclosed, Admescope will licence the TRAC technology for its toxicological testing services unit.
-------
AIM ALL-SHARE LOSERS
-------
African Copper, off 84%. The company said it will seek approval from shareholders to cancel its trading on AIM and in Botswana at a general meeting to be held towards the end of May due to the company's size and lack of liquidity, a proposition that has already gained support from the company's largest shareholders. It said it is suffering from a "lack of demand" for its shares which is making it difficult to use the listings to raise money from investors, adding that the "low liquidity" in the company's shares could lead to "volatility" in the share price.

MXC Capital, down 17%. The merchant bank said it has raised GBP11.7 million after expenses in a placing of 480.0 million new share priced at 2.5 pence each. In a statement, it said it will use the money raised and cash it already has to "pursue a number of near-term, identified opportunities and further develop a growing pipeline of future opportunities". The company's shares currently trade at 3.173p.

Red Rock Resources, down 16%. The gold explorer said it has moved to protect its interests in Kenya after the country's Ministry of Mining told the company's local partner that it had terminated two special licenses, although it warned that it may have to book a further writedown on its Kenyan assets if it doesn't get a positive result quickly.

Asian Citrus Holdings, down 11%. The company said it expects the 2015 winter harvest from its Xinfeng Plantation to be significantly reduced compared with the previous year, which in turn will have a knock-on effect for its results in the year to end-June 2016, as it tackles Huanglongbing disease amongst its orange trees.
-------

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
31 Mar 2023 16:39

TRADING UPDATES: FireAngel signs with British Gas; Shanta pours gold

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
1 Mar 2023 20:09

TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Mar 2023 14:26

ValiRx incorporates new wholly-owned lab subsidiary

(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.

Read more
3 Feb 2023 13:41

TRADING UPDATES: Somero revenue short of outlook; SigmaRoc optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
26 Jan 2023 15:44

UK shareholder meetings calendar - next 7 days

Friday 27 January 
Avon Protection PLCAGM
Henderson Far East Income LtdAGM
Ixico PLCAGM
NB Global Monthly Income Fund LtdEGM re proposed managed wind-down
On The Beach Group PLCAGM
Pathfinder Minerals PLCGM re capital raise
Serica Energy PLCGM re consideration shares approval
Treatt PLCAGM
Monday 30 January 
Bluebird Merchant Ventures LtdAGM
Contango Holdings PLCAGM
Hollywood Bowl Group PLCAGM
SkinBioTherapeutics PLCGM re annual report review
Starwood European Real Estate Finance LtdEGM re capital return 
Webis Holdings PLCAGM
Tuesday 31 January 
Hydrogen Future Industries PLCAGM
Mobile Streams PLCAGM
Residential Secure Income PLCAGM (TBC)
Star Phoenix Group LtdGM re removal and appointment of auditor
Team PLCAGM
Yamana Gold IncSGM re transaction with Agnico Eagle Mines Ltd and Pan American Silver Corp
Zamaz PLCAGM
Wednesday 1 February 
Baronsmead Second Venture Trust PLCAGM
Baronsmead Venture Trust PLCAGM
Capricorn Energy PLCGM re directors removal and appointment of new directors
Catalyst Media GroupAGM
Hyve Group PLCAGM
Imperial Brands PLCAGM
Premier Miton Group PLCAGM
Renew Holdings PLCAGM
Schroder Asia Pacific Fund PLCAGM
Thursday 2 February 
abrdn Equity Income Trust PLCAGM
Alteration Earth PLCAGM
Baillie Gifford European Growth Trust PLCAGM
JPMorgan Indian Investment Trust PLCAGM
Sage Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Tectonic Gold PLCAGM
ValiRx PLCGM re fundraising
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Jan 2023 21:40

TRADING UPDATES: Future Metals in JV; Gunsynd sells stake in investee

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Jan 2023 13:31

IN BRIEF: ValiRx seeks up to GBP1.5 million for new research facility

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation.

Read more
6 Dec 2022 11:31

ValiRx shares fall on test extension, but optimistic of other assets

(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing.

Read more
24 Oct 2022 12:47

ValiRx forms new majority-owned breast cancer subsidiary

(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).

Read more
24 Oct 2022 10:05

ValiRx teams with King's College London for cancer project

(Alliance News) - ValiRx PLC on Monday said it is making progress on its goal to introduce new academic projects into its portfolio, after launching subsidiary company Cytolytix Ltd and signing a licence agreement with King's College London.

Read more
8 Sep 2022 11:47

IN BRIEF: ValiRx shares up on new interim chief scientific officer

ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: "I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."

Read more
31 Aug 2022 13:51

EARNINGS UPDATES: Windward widens loss as operating expenses rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Jul 2022 14:44

IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress

ValiRx PLC - Nuneaton, England-based drug development company - Completes the evaluation of the impact of a peptide drug candidate against triple negative breast cancer. Evaluation concludes there is "good evidence" of biological activity and a "strong" rationale for further development. Adds that the drug candidate was investigated over nine months. Tests also demonstrate promising data on ovarian cancer cells, in addition to the targeted breast cancer cells. As a result, ValiRx has notified the academic team and intellectual property & licensing team at King's College London that it wants to proceed to full in-licensing.

Read more
5 Jul 2022 15:51

IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option

ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.

Read more
30 Jun 2022 17:31

TRADING UPDATES: M&C Saatchi expects to deliver on annual profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.